These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2930896)

  • 1. Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates.
    Astedt B; Bladh B; Christensen U; Lecander I
    Scand J Clin Lab Invest; 1985 Sep; 45(5):429-35. PubMed ID: 2930896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator.
    Astedt B; Lecander I; Brodin T; Lundblad A; Löw K
    Thromb Haemost; 1985 Feb; 53(1):122-5. PubMed ID: 3922076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human and ovine acrosomal enzymes by tannic acid in vitro.
    Taitzoglou IA; Tsantarliotou M; Zervos I; Kouretas D; Kokolis NA
    Reproduction; 2001 Jan; 121(1):131-7. PubMed ID: 11226036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
    Turner PC; Baquero MT; Yuan S; Thoennes SR; Moyer RW
    Virology; 2000 Jul; 272(2):267-80. PubMed ID: 10873770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
    Nishida Y; Hayashi Y; Imai Y; Itoh H
    Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and characterization of placental plasminogen activator (PPA).
    Kobayashi T; Terao T
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 May; 37(5):783-92. PubMed ID: 3923141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor.
    Lecander I; Roblin R; Astedt B
    Br J Haematol; 1984 Jul; 57(3):407-12. PubMed ID: 6430331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor.
    Chapman HA; Stone OL
    Biochem J; 1985 Aug; 230(1):109-16. PubMed ID: 2932100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interfering factors in the assay of plasminogen activators by the fibrin plate method. Occurrence of different inhibitors against tissue plasminogen activator and urokinase.
    Wijngaards G
    Thromb Haemost; 1979 May; 41(3):590-600. PubMed ID: 111368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A spectrophotometric assay for the determination of the catalytic efficiency of plasminogen activators using a slowly hydrolyzed plasmin substrate.
    Castro MJ; Kingston IB; Anderson S
    Anal Biochem; 1995 Apr; 226(2):225-31. PubMed ID: 7793622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assay method for single-chain urokinase-type plasminogen activator.
    Matsuo O; Ueshima S; Okada K; Fukao H; Ohgaki M; Watanabe R; Arimura H
    Hematol Pathol; 1989; 3(3):137-42. PubMed ID: 2531734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.
    Holmberg L; Lecander I; Persson B; Astedt B
    Biochim Biophys Acta; 1978 Nov; 544(1):128-37. PubMed ID: 152655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional assay of plasminogen activator by hydrolysis of 14C-globin.
    Finci Z; Nachshon I; Sharoni Y; Mayer M
    Exp Hematol; 1986 May; 14(4):293-7. PubMed ID: 2938980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actin stimulates plasmin generation by tissue and urokinase-type plasminogen activators.
    Lind SE; Smith CJ
    Arch Biochem Biophys; 1993 Nov; 307(1):138-45. PubMed ID: 8239651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibition of esterase by L-lysine, the activator and fibrinolytic activity of the plasmin-streptokinase activator complex].
    Aĭsina RB; Gaĭsarian ES; Snitko IaE; Varfolomeev SD
    Bioorg Khim; 1994 Feb; 20(2):182-9. PubMed ID: 8155080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification and characterization of single-chain urokinase-type plasminogen activator (pro-urokinase) from human A431 cells.
    Corti A; Nolli ML; Soffientini A; Cassani G
    Thromb Haemost; 1986 Oct; 56(2):219-24. PubMed ID: 3101222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.